Lumentum (LITE) Options Chain & Prices

Early human trial data from one NASDAQ-listed biotech showed up to a 63.7% reduction in cancer burden using its TriKE platform, which is designed to keep Natural Killer cells active and targeted longer than standard approaches. The company's next-generation version shows potential for 10-40x greater potency and has already cleared an important FDA milestone. Watch the microscopic footage and see what the next catalyst could mean for investors.

Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.

Goldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst environment in 50 years - with portfolios potentially staying in the red for 10 years or longer. From rate spikes in 2022 to $12 trillion wiped out in 30 days during the Iran War, Wall Street suggests the volatility isn't slowing down. TradeSmith CEO Keith Kaplan is showing investors what steps to take now to prepare their wealth before this worsens.